NCT07168837Completed
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction Among PCOS Patients in Assiut Governorate
Source: ClinicalTrials.gov · Last updated 11 Sept 2025
Brief summary (registry, in English)
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide. Owing to the intricacy of this condition, various sets of diagnostic criteria have been initiated for the confirmation of PCOS which are: National Institute of Health, Rotterdam's Criteria, Androgen Excess and PCOS society. The prevalence of PCOS is estimated at about 4 to 21 % when it is diagnosed according to the Rotterdam criteria accounting for 75% of cases with anovulatory infertility.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 4 Sept 2025
- Start date
- 10 Jan 2023
- Primary completion date
- 1 May 2024
- Lead sponsor
- Al-Azhar University
- NCT number
- NCT07168837
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From 10 Jan 2023 to the primary completion date, 1 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with liver and kidney disease.
Other
- Congenital adrenal hyperplasia.
- Hypothalamic or pituitary cause of amenorrhea.
- Primary hyperprolactinemia.
Who the study is looking for
- Women diagnosed with PCOS according to Rotterdam criteria (Rotterdam, 2004) as:
- Menstrual anomalies like amenorrhea (no cycles in the past 6 months), oligomenorrhoea (cycles lasting longer than 35 days), or long cycles.
- Clinical and/or biochemical hyperandrogenism.
- Ultrasound (USG) appearance of polycystic ovaries (multiple cysts \>12 in number of 2-9 mm size).
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Azhar University Hospitals Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.